Drug Trial Radar · NCT03201562
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Apr 30, 2017
Primary completion
May 20, 2018
Study completion May 20, 2018
Sponsor
- Lead sponsor
- LENZ Therapeutics, IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 48 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in the treatment of early to moderate presbyopia.
Conditions
- Presbyopia
Interventions
Aceclidine+tropicamide combinationDrug
Ophthalmic Solution
AceclidineDrug
Ophthalmic Solution
VehicleDrug
Ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study EyeTime frame: 1 hour post-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andover Eye Associates
Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.